Company profile
Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Lorundrostat Hydrobromide | phase2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05769608 | phase2 | completed | 2023-03-13 | 2025-01-15 | Mineralys Therapeutics Inc. | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
| NCT06785454 | phase2 | completed | 2025-02-28 | 2025-12-17 | Mineralys Therapeutics Inc. | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension |
| NCT06150924 | phase2 | completed | 2023-12-14 | 2025-02-27 | Mineralys Therapeutics Inc. | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria |
| NCT06153693 | phase3 | completed | 2023-11-22 | 2024-12-10 | Mineralys Therapeutics Inc. | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
| NCT05968430 | phase3 | active_not_recruiting | 2023-07-14 | 2025-12-30 | Mineralys Therapeutics Inc. | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension |
FDA applications (0)
No records yet.